1887
Rapid communications Open Access
Like 0

Abstract

The 2012/13 influenza season in Canada has been characterised to date by early and moderately severe activity, dominated (90%) by the A(H3N2) subtype. Vaccine effectiveness (VE) was assessed in January 2013 by Canada's sentinel surveillance network using a test-negative case-control design. Interim adjusted-VE against medically attended laboratory-confirmed influenza A(H3N2) infection was 45% (95% CI: 13-66). Influenza A(H3N2) viruses in Canada are similar to the vaccine, based on haemagglutination inhibition; however, antigenic site mutations are described in the haemagglutinin gene. .

Loading

Article metrics loading...

/content/10.2807/ese.18.05.20394-en
2013-01-31
2017-11-24
http://instance.metastore.ingenta.com/content/10.2807/ese.18.05.20394-en
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/18/5/art20394-en.htm?itemId=/content/10.2807/ese.18.05.20394-en&mimeType=html&fmt=ahah
Comment has been disabled for this content
Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error